Last $3.80 USD
Change Today -0.09 / -2.31%
Volume 153.3K
SRNE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Open
$3.80
Previous Close
$3.89
Day High
$3.91
Day Low
$3.70
52 Week High
03/21/14 - $16.40
52 Week Low
10/14/14 - $3.10
Market Cap
109.9M
Average Volume 10 Days
76.3K
EPS TTM
$-1.83
Shares Outstanding
28.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SORRENTO THERAPEUTICS INC (SRNE)

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as well as immunodeficiencies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

50 Employees
Last Reported Date: 04/1/14
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $291.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

sorrento therapeutics inc (SRNE) Key Developments

Sorrento Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 03:00 PM

Sorrento Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 03:00 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Henry H. Ji, Co-Founder, Chief Executive Officer, President and Director.

Sorrento Therapeutics, Inc. Presents at Drexel Hamilton Micro-Cap Investor Forum 2014, Nov-13-2014 01:00 PM

Sorrento Therapeutics, Inc. Presents at Drexel Hamilton Micro-Cap Investor Forum 2014, Nov-13-2014 01:00 PM. Venue: Drexel Hamilton's offices, 77 Water Street Downtown, New York, New York, United States.

Sorrento Therapeutics, Inc. Announces Positive Results from Pharmacokinetic Data Enrolled in its Ongoing TRIal Establishing Bioequivalence Between Cynviloq(TM) and Albumin-Bound Paclitaxel Registrational Trial

Sorrento Therapeutics, Inc. announced positive results from recently analyzed pharmacokinetic data from the first eight patients enrolled in its ongoing TRIBECA(TM) (TRIal establishing BE between Cynviloq(TM) and Albumin-bound paclitaxel) registrational trial. The data from these patients supports earlier completion of the study with the aim of seeking to establish bioequivalence (BE) to albumin-bound paclitaxel to obtain Food and Drug Administration (FDA) marketing approval for Cynviloq (paclitaxel polymeric micelle for injection). Sorrento amended the current BE cross-over design protocol of the TRIBECA study to un-blind the first 8 patients to reassess the sample size of 100 patients estimated from simulation of historical PK data. Based on the cross-over data and the analyses of relevant paclitaxel plasma PK data performed by two independent PK consulting groups, the success of the BE approach for seeking approval of Cynviloq remains subject to FDA review and discussion. Sorrento does not plan to un-blind additional patient data. Current sample size point estimates suggest that the enrollment target for the current study can be reduced to nearly half of the original target.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $3.80 USD -0.09

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies
 

Industry Analysis

SRNE

Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.7x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit www.sorrentotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.